PF-Atlas › Clinical Trials › NCT06549231
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
Rituximab · Phase 3
Registry ID
NCT06549231
Phase
Phase 3
Status
Recruiting
Drug / intervention
Rituximab
Sponsor
University Hospital, Tours
Start
2025-01-08
Enrollment
102
Locations
1
About this trial
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at high risk of progression.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT06549231 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.